BMO Capital Reiterates Bristol-Myers Squibb (BMY) Outperform, Bempeg in Melanoma Was Incremental to BMY's Thesis
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $74.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
